Общество с ограниченной ответственностью "Трейдсервис" (RU)
发明人:
Алексенко Павел Владимирович (RU)
申请号：
RU2013131957/15
公开号：
RU2013131957A
申请日:
2013.07.09
申请国别(地区):
RU
年份:
2015
代理人:
摘要：
1. Dosage form hypolipidemic action, comprising as active ingredient rosuvastatin, or a pharmaceutically acceptable salt thereof in an amount of from 3 to 15%, processing aids, and a pharmaceutically acceptable excipient comprising microcrystalline cellulose, lactose monohydrate, polivinilpirrolidol (povidone) and sodium croscarmellose, wherein said the filler is a granulate in an amount of from 79 to 95% by weight of the dosage form with moisture content adsorbed in the range from 0.5% to 1.5% .2. A dosage form according to Claim. 1, wherein said microcrystalline cellulose is contained in the range of from 11 to 13% by weight of the dosage formy.3. A dosage form according to Claim. 1, wherein said lactose monohydrate is contained in the range of from 60 to 81% by weight of the dosage formy.4. A dosage form according to Claim. 1, wherein the povidone is contained in the range of from 2 to 3% by weight of the dosage formy.5. A dosage form according to Claim. 1, wherein said croscarmellose sodium is contained in the range of from 1 to 3% by weight of the dosage formy.6. A dosage form according to claim. 1, where the composition of the dosage form comprises an outer faza.7. A dosage form according to claim. 6, wherein said outer phase is from 2 to 6% by weight of the dosage formy.8. A dosage form according to claim. 6, wherein in the composition the external phase contains magnesium stearate in the range of from 0.5 to 1.5% by weight of the dosage formy.9. A dosage form according to claim. 6, wherein in the composition the external phase contains colloidal silica in the range from 0.5 to 1.5% by weight of the dosage formy.10. A dosage form according to claim. 6, wherein in the composition the external phase contains sodium croscarmellose in the range from 1 to 3% by weight of the drug1. Лекарственная форма гиполипидемического действия, содержащая в качестве активного ингредиента розувастатин или его фармацевтически приемлемую соль в количестве от 3 до 15%, технологичес
